Press release
Study Shows Dupixent Users Face 4.5X Higher Cancer Risk
JAMA Dermatology Study Shows 4.5-Fold Increased Risk of Cutaneous T-Cell Lymphoma in Patients Using Dupixent for Eczema Treatment.Orlando, FL - November 16, 2025 - Idillo Inc., a leading mass tort case generation company, today announced the launch of https://getafreecasereview.com/dupixent/, a comprehensive online resource providing free case evaluations for individuals who developed cancer after using Dupixent (dupilumab).
The initiative comes in response to growing litigation surrounding Dupixent, a prescription medication manufactured by Sanofi and Regeneron Pharmaceuticals. Research published in JAMA Dermatology in 2023 found that Dupixent users faced a 4.5-fold increased risk of developing cutaneous T-cell lymphoma (CTCL) compared to non-users (Ständer et al., JAMA Dermatology, 2023).
"Our mission is to provide accurate, research-backed information to help individuals understand their legal rights," said Hans Peter Jeschke, CEO of Idillo Inc. "The 2023 JAMA Dermatology study documented a statistically significant cancer risk that many Dupixent users were never warned about. We connect these individuals with experienced mass tort attorneys who can evaluate their claims at no cost."
Key findings about Dupixent and cancer risk include:
- Dupixent users face 4.5 times higher risk of cutaneous T-cell lymphoma (CTCL)
- Risk increases with longer duration of use
- Study analyzed data from over 20,000 patients
- First wrongful death lawsuit filed in October 2025
- Litigation is in early stages with bellwether trials anticipated in 2027
Individuals may qualify for compensation if they used Dupixent for three months or longer and were subsequently diagnosed with CTCL, mycosis fungoides, or Sézary syndrome. Eligibility requirements and case evaluation forms are available at https://getafreecasereview.com/dupixent/.
Settlement amounts in similar pharmaceutical mass tort cases have ranged from $250,000 to over $5,000,000 depending on severity of injury, age at diagnosis, and extent of medical treatment required. Attorneys handling these cases work on contingency, meaning no upfront costs for plaintiffs.
"Dupixent generated over $11 billion in annual sales," Hans Peter Jeschke noted. "If manufacturers failed to adequately warn patients about serious cancer risks, they should be held accountable. Our service connects harmed individuals with legal resources to pursue that accountability."
The free case evaluation process involves no obligation and all information is confidential. Individuals can complete an online questionnaire at https://getafreecasereview.com/dupixent/ or contact Idillo Inc. directly for more information.
###
SOURCE: Idillo Inc.
CITATION: Ständer S, et al. Association Between Dupilumab Use and Cutaneous T-Cell Lymphoma in Patients With Atopic Dermatitis. JAMA Dermatology. 2023;159(8):821-827.
Idillo Inc.
1317 Edgewater Dr 2163
Orlando, FL 32804
Idillo Inc. is a Florida-based marketing and advertising company specializing in mass tort case generation and legal lead services. The company connects individuals harmed by defective drugs, medical devices, and dangerous products with experienced mass tort attorneys nationwide. Idillo Inc. is not a law firm and does not provide legal advice. More information is available at https://getafreecasereview.com.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Study Shows Dupixent Users Face 4.5X Higher Cancer Risk here
News-ID: 4272304 • Views: …
More Releases for Dupixent
Dupixent for Moderate-to-Severe Asthma Treatment Market Size, Clinical Trials, P …
Dupixent for Moderate-to-Severe Asthma Treatment Market Size is estimated to be $3250 million in 2024 and is expected to grow at an average yearly rate of around 14% during the timeframe (2025-2032).
What is Dupixent for Moderate-to-Severe Asthma Treatment and what are the growth drivers of Dupixent for Moderate-to-Severe Asthma Treatment Market?
Dupixent (dupilumab) is a biologic medication developed to treat moderate-to-severe asthma, particularly in patients with type 2…
Dupixent Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportunit …
The Dupixent Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Dupixent Market?
In recent years, the market size for Dupixent has seen a HCAGR of XX. Projected growth indicates a rise from $XX million in 2024 to $XX million…
Key Trend Reshaping the Dupixent Market in 2025: Innovations In Biologic Medicin …
What industry-specific factors are fueling the growth of the dupixent market?
The escalating incidence of skin allergies is predicted to be a key factor contributing to the expansion of the dupixent market. Immune system responses to substances causing skin irritation or inflammation, collectively referred to as skin allergies, result in symptoms such as redness, itching, rashes or swelling. These skin allergies are increasing due to aspects like increasing environmental pollution, altered…
Innovations In Biologic Medicines Drive Dupixent Market Growth Trend: A Crucial …
What Is the Expected Size and Growth Rate of the Dupixent Market?_x000D_
In the past few years, the Dupixent market size has recorded an $XX. There is an anticipation for growth from $XX million in 2024 up to $XX million in 2025 with a compound annual growth rate (CAGR) of $XX%. This expected hike can be traced back to the heightened demand for innovative treatment options, patient advocacy and increased public…
DUPIXENT Market Size expected to increase many folds by 2032, reports DelveInsig …
[Las Vegas, United States] (14th March 2024) The Latest report, DUPIXENT Market Size, Forecast, and Drug Insight 2032 is published by DelveInsight, a leader in healthcare research firm, providing insights into the DUPIXENT market landscape and market forecast of DUPIXENT up to 2032. This report is now available for review and analysis.
Are you interested in finding out the projected market size of DUPIXENT in 2032? Click @ DUPIXENT Market Size-…
DUPIXENT Market Size and Share Analysis Across 7MM and Competitive Landscape by …
DelveInsight has released a comprehensive report titled "DUPIXENT Market Forecast" offering a thorough examination and predictive insights into the DUPIXENT market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of DUPIXENT in the therapeutics landscape for Atopic Dermatitis across the 7MM…
